Anti-inflammatory effects of ω-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension.
about
PPAR Ligands Function as Suppressors That Target Biological Actions of HMGB1Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacyDietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathwayCytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolismSoluble Epoxide Hydrolase in Hydrocephalus, Cerebral Edema, and Vascular Inflammation After Subarachnoid HemorrhageSoluble epoxide hydrolase: gene structure, expression and deletionStabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancerEffect of soluble epoxide hydrolase polymorphism on substrate and inhibitor selectivity and dimer formationEpoxyeicosatrienoic acids, hypertension, and kidney injuryThe 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic painAn ω-3-enriched diet alone does not attenuate CCl4-induced hepatic fibrosisOmeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE₂ induced pain modelOral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU): Resulting drug levels and modulation of oxylipin patternAn omega-3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension.Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7PPARδ signaling mediates the cytotoxicity of DHA in H9c2 cells.Soluble epoxide hydrolase null mice exhibit female and male differences in regulation of vascular homeostasisAssociations of Whole Blood n-3 and n-6 Polyunsaturated Fatty Acids with Blood Pressure in Children and Adolescents - Results from the IDEFICS/I.Family CohortInhibition of soluble epoxide hydrolase as a novel approach to high dose diazepam induced hypotension.Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases.Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases.Modulation of the endogenous omega-3 fatty acid and oxylipin profile in vivo-A comparison of the fat-1 transgenic mouse with C57BL/6 wildtype mice on an omega-3 fatty acid enriched diet.Diabetic macular edema, retinopathy and age-related macular degeneration as inflammatory conditionsSignificance of long chain polyunsaturated fatty acids in human health.Novel Omega-3 Fatty Acid Epoxygenase Metabolite Reduces Kidney Fibrosis.Potential role of polyunsaturated fatty acids in diabetic retinopathy.Epoxide metabolites of arachidonate and docosahexaenoate function conversely in acute kidney injury involved in GSK3β signaling.Probing the orientation of inhibitor and epoxy-eicosatrienoic acid binding in the active site of soluble epoxide hydrolase.EPA:DHA 6:1 prevents angiotensin II-induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase- and COX-derived oxidative stress.Epoxide hydrolase 1 (EPHX1) hydrolyzes epoxyeicosanoids and impairs cardiac recovery after ischemia.
P2860
Q26738811-3CBCAFF6-24B8-4252-BA07-E518550B3281Q27684895-9D23E466-BA07-4140-A733-7CE07D2E2730Q28235974-A7000AF9-33BF-4A46-A6EF-D5F4616DA92DQ28245279-3EAD913C-A3C9-428A-997E-4CDB5049E054Q28262216-14AA51B2-4D4D-40C2-9181-F350C200121AQ28291292-11D6D214-C456-4B40-ACFB-972812D74014Q28304230-C0BB2790-51B9-453E-8650-82B6065A5548Q28386561-DFFA6454-F83E-403F-97A3-2D2E23910DDDQ28387823-6AA9C489-ED9A-44F8-B628-15A634E325C8Q28392416-041FB8E8-F3AE-42CD-B3FA-9423038162A9Q28393724-85D9C060-B5E8-4251-B31E-60826A7BED9AQ28395323-AE81857F-D011-46F0-9F21-B19885521AB7Q28397238-B84D3CBD-7BD8-4325-8B08-507248616FF6Q33882374-3D89AE43-B1B9-4B09-A3EA-05B019FD213AQ34774458-4FB667A9-095A-4923-8600-6E19BD6B6559Q35802150-3788C4E6-40BE-4F34-B426-840C6BEBA3B2Q36074375-AF46CFF0-3802-42C1-AB5D-ECC68C33B073Q36180513-94AC7622-F62C-4D73-B9C5-466840CDD8F3Q37670034-2A345049-33E9-4647-AC24-B80ECBBBD4D4Q38184587-DF100EE9-C296-40ED-BA3F-0FA447CE056BQ39392465-5FDAA7B4-DBF9-40C0-BBE5-52B2E20CED97Q40060262-57EECA87-899C-4B70-9E7B-7A21D177AAA8Q41049002-5C7CCBE7-8D23-4B3F-9978-30B873FAAD39Q41158349-CD348F43-F0BA-4A13-AE21-C45567D18530Q41981357-B1B4DE40-936C-4449-8005-2FDD8CA856E2Q43107948-602A144B-1B13-4849-8657-3EAEE0CFD4E1Q46028902-CA5DC806-69E7-489E-BC3E-A4B5F7A2C1FAQ46078832-D548D44E-6390-47FF-9C83-DA7963BF9A8DQ47845782-0457A17B-A9BC-4ABF-B977-AB96078AFAC5Q49336465-A9D78E03-142D-4FB5-9D78-5D0E614087F5
P2860
Anti-inflammatory effects of ω-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-inflammatory effects of ω ...... sin-II-dependent hypertension.
@en
Anti-inflammatory effects of ω ...... sin-II-dependent hypertension.
@nl
type
label
Anti-inflammatory effects of ω ...... sin-II-dependent hypertension.
@en
Anti-inflammatory effects of ω ...... sin-II-dependent hypertension.
@nl
prefLabel
Anti-inflammatory effects of ω ...... sin-II-dependent hypertension.
@en
Anti-inflammatory effects of ω ...... sin-II-dependent hypertension.
@nl
P2093
P2860
P50
P921
P1476
Anti-inflammatory effects of ω ...... nsin-II-dependent hypertension
@en
P2093
Bruce D Hammock
Christina Miyabe
Christophe Morisseau
Gertrud Schuster
Hiromi Inoue
Nipavan Chiamvimonvat
Robert H Weiss
Todd R Harris
P2860
P304
P356
10.1097/FJC.0B013E318298E460
P407
P577
2013-09-01T00:00:00Z